Programme

Overview: Online adaptive radiotherapy challenges clinical teams across multiple aspects, including implementation, resources, and education. While continuing professional development is well addressed, the question of initial RTT education remains open. In this debate, four international expert RTTs will explore whether educational programmes require a major overhaul to support the implementation of this major innovation. Rianne de Jong and Claudio Votta will argue in favour of a substantial overhaul, emphasising that online adaptive radiotherapy requires RTTs to acquire new and advanced skills. Opposing them, Helen McNair and Winnie Li will advocate for targeted adaptations within existing frameworks. The stage is set for a stimulating debate, but who will present the stronger arguments? That is for you, the audience, to decide by attending and casting your vote!

Overview: Brachytherapy continues to play a pivotal role in modern radiation oncology, offering highly conformal dose delivery and unique radiobiological advantages. This symposium will highlight the most recent clinical and technological advances across major disease sites where brachytherapy remains a cornerstone of treatment. Leading experts will present key innovations in prostate and breast brachytherapy, developments in treatment planning and physics, and new insights in gynecological, head-and-neck, and skin brachytherapy. The session will provide a concise overview of emerging techniques, technological progress, and clinical evidence shaping the future of brachytherapy, emphasizing its continued relevance within precision radiation oncology.

Overview: It has been, for many years, the aim of many medical physicists in our field to ensure precision of our treatments. Delineation, treatment planning, image guidance, machine QA, plan QA all seem to aim for the highest precision achievable. Indeed, in recent years, the precision of our treatments has become excellent. However, still, a lot of effort is spent improving or maintaining this precision. Simultaneously, healthcare costs are rising, our workforce is under pressure and we can only spent our time once. Is it still worthwhile to spent resources in trying to improve the precision of our treatments, or have we reached a plateau where ‘good’ is actually ‘good enough’? Should we continue to pursue the highest precision, or is it enough to be “as precise as reasonably achievable”?